Turning the Tide - Annual Report 2017 from TB Alliance
"2017 was a year of meaningful progress in the search for new drugs for TB, which is still the deadliest infectious disease worldwide."
Findings from our late-stage clinical trials show promise for patients. Interim results from the Nix-TB clinical trial have indicated the potential of a three-drug combination of bedaquiline, pretomanid and linezolid (or "BPaL") to treat those with some of the most resistant - and deadliest - forms of the disease including extensively drug-resistant TB (XDR-TB) and treatment intolerant/nonresponsive multidrug-resistant TB (MDR-TB).
Separately, a four-drug regimen of bedaquiline, pretomanid, moxifloxacin and pyrazinamide (or "BPaMZ") was studied in the NC-005 clinical trial. Results from this trial indicate that BPaMZ may be an appropriate treatment that, together with the BPaL regimen, could provide treatment solutions for the more than 10 million people who develop active TB each year.
A new trial, called ZeNix, which is further evaluating the BPaL drug regimen, was launched in late 2017. ZeNix is assessing whether the efficacy of the BPaL regimen can be maintained while reducing toxicity by testing a lower dose and shorter duration of the drug linezolid. Another trial, called SimpliciTB, will begin in 2018. It is a late stage trial that will evaluate the BPaMZ regimen in people with drug-sensitive TB (DS-TB) and MDR-TB.
Efforts to bring new TB drugs to the world must extend far beyond the treatments that are closest to fruition. We continued to see meaningful growth and progression of the pipeline with the initiation of two phase 1 clinical trials that, if successful, could help secure the future of TB therapy for years to come.
You may also like to read an article about: community-based tuberculosis screening
by PhD student Olivia Biermann, Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden
All fields marked with an * are compulsory